CD5 and myeloid sarcoma: Further, in MS patients, we found upregulation of markers for autoimmune inflammation such as IL-32, for T cell activation such as CD52 and for T cell homing such as CCR7 in CD5+ CD4+ T cells compared with CD5− CD4+ T cells (Fig. 5A and Supplementary Table 6).